glp 1 agonist tirzepatide Major physiological roles of GLP-1 and GIP. is acting as an SEMA vs TIRZ vs RETA
Description
By mimicking the GLP-1 hormone, Semaglutide enhances insulin secretion, reduces glucagon release, and slows gastric emptying, leading to improved glycemic control
Treatment starts with 0.25 mg once weekly for 4 weeks as an initiation dose (not for glycaemic control), then increases to 0.5 mg once weekly
For example, AUXORA in the US is expected to be launched by 2025 with a peak share of 12%
Progress depends on consistency, proper dosing, and whether supportive therapies like lipotropics or wellness injections are included
They look slimmer, fitter, and more toned after completing their treatment plans
